A novel chiral oxazoline copper( ii )-based complex inhibits ovarian cancer growth in vitro and in vivo by regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors
Dalton Transactions · 2023 · 52 (33) · 11427-11440
DOI: 10.1039/d3dt01648j ↗Kurz gefasst
Fachartikel in der Zeitschrift Dalton Transactions, 2023. Verfasst von Rong Fan und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Guilin Medical University, Guangxi, Guilin, 541004, China. xyqin6688@163.com. Hauptthemen laut MEDLINE: Copper, Ovarian Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
An oxazoline-coordinated copper complex regulates the VEGF/VEGFR2 signaling pathway and apoptosis-related factors to resist ovarian cancer in vivo and in vitro .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Guilin Medical University, Guangxi, Guilin, 541004, China. xyqin6688@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fan, R., Wei, J. C., Xu, B. B., Jin, N., Gong, X. Y., & Qin, X. Y. (2023). A novel chiral oxazoline copper( ii )-based complex inhibits ovarian cancer growth in vitro and in vivo by regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors. Dalton Transactions, 52(33), 11427-11440. https://doi.org/10.1039/d3dt01648j
Vancouver
Fan R, Wei JC, Xu BB, Jin N, Gong XY, Qin XY. A novel chiral oxazoline copper( ii )-based complex inhibits ovarian cancer growth in vitro and in vivo by regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors. Dalton Transactions. 2023;52(33):11427-11440. doi:10.1039/d3dt01648j
BibTeX
@article{Fan2023,
author = {Fan, Rong and Wei, Jing-Chen and Xu, Bing-Bing and Jin, Nan and Gong, Xiao-Yi and Qin, Xiu-Ying},
title = {A novel chiral oxazoline copper( ii )-based complex inhibits ovarian cancer growth in vitro and in vivo by regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors},
journal = {Dalton Transactions},
year = {2023},
volume = {52},
number = {33},
pages = {11427--11440},
doi = {10.1039/d3dt01648j}
}
EUVIMED